BOARD OF DIRECTORS

OxThera is built on a highly experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing.

Board of Directors

Georges Gemayel
Chairman

Martijn Kleijwegt

Rémi Droller

Lance Berman

Sten Verland

Maarten de Chateau

Jonas Brambeck

Alain Munoz

Anders Fink Vadsholt

Georges Gemayel, Chairman

Georges Gemayel has served as Chairman for OxThera since October 2013. From February 2011 to December 2012, Dr. Gemayel served as executive chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010 Dr. Gemayel served as executive chairman of FoldRx Pharmaceuticals, Inc. until its acquisition by Pfizer Inc. From June 2008 until November 2009, Dr. Gemayel served as president and chief executive officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for Genzyme Corporation’s global therapeutics, transplant, renal and biosurgery businesses. Dr. Gemayel currently serves as chairman of the boards of directors of Enterome Bioscience SA and Dynacure, both privately held companies. He serves as Chairman of Orphazyme and as a Director of Momenta Pharmaceuticals, and Supernus Pharmaceuticals, Inc, all publicly listed companies.

Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in pharmacology from Paris-Sud University in Paris, France.

Martijn Kleijwegt

Martijn Kleijwegt founded Life Sciences partners (LSP) in 1998 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and in the general management of the firm. Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector. As one of Europe’s most experienced healthcare investors, Martijn brings over 30 years of hands-on finance and investment experience to the LSP team. He has also been appointed Director of a large number of companies, amongst others Qiagen GmbH, Crucell N.V., Movetis N.V., Prosensa Holding N.V. and Kiadis Pharma, all of which he helped to grow and flourish.

Rémi Droller

Rémi Droller is a Managing Partner at Kurma Partners. Rémi was previously Partner at Idinvest Partners where he developed investment activity in the life sciences. Rémi serves on the board of AM Pharma, Orphazyme (listed on Nasdaq Copenhagen), Dynacure, Pharvaris, ImCheck. Rémi holds a MS in molecular biology (Paris VI University) and MS in finance and Innovation management (AgroPariTech).

Lance Berman

Lance Berman is a Venture Partner at Ysios and brings over 20 years of clinical development, medical affairs and corporate leadership experience in both the big pharma and small biotech start-up spaces. Prior to joining Ysios, Lance was Chief Medical Officer and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the Company’s clinical development, medical affairs and drug safety functions; as well as playing a key role in the preparation and execution of the Company’s fund-raising initiatives including the Company’s IPO. Under his clinical leadership, the Company secured FDA and EMA approval for VeltassaÒ. Prior to Relypsa Lance was Chief Medical Officer at CPEX Pharmaceuticals until its acquisition. Previously, Lance held roles of increasing responsibility at Pfizer Inc., Schering-Plough Corporation (merged with Merck) and at Janssen Pharmaceuticals, Inc. (Johnson & Johnson). In addition to having worked across multiple therapeutic areas, he has also worked closely with commercial teams to secure product reimbursement and to plan and execute product launches. Lance received his Bachelor of Medicine and Bachelor of Surgery degree from the University of Cape Town, South Africa and holds a Master’s in Science (Pharmaceutical Medicine).

Sten Verland

Sten Verland is a Senior Partner of Sunstone Life Science Ventures and one of the three co-founders of Sunstone. Dr. Verland has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. Dr. Verland has played a key role in executing three M&As (Rigontec, Action Pharma and Zymenex) and one IPO (Orpahzyme). He currently serves on the Board of Directors of Orphazyme A/S, Vaximm AG, Anergis SA, Minervax ApS and the Danish Venture Capital Association (DVCA).

Dr. Verland holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen.

Maarten de Chateau

Maarten de Chateau is currently CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the board of Atrogi, and on the boards of AddBio, Cavis Technologies and Gesynta Pharma. Maarten was Co-founder and CEO of Cormorant Pharmaceuticals. The company developed a therapeutic antibody approach in immuno-oncology and was acquired by Bristol-Myers Squibb in 2016. Prior to that, Maarten held the position of Medical Director at Swedish Orphan Biovitrum, with medical and clinical development responsibility for two marketed products in the rare disease space. Before that, he worked in clinical development at Sanofi and also as a financial analyst at two investment banks for five years.

Jonas Brambeck

Jonas Brambeck is Investment Manager at Industrifonden and responsible for investments in the Life Science area. Dr Brambeck has more than twenty years’ experience from venture capital within Life Science. He serves on the Board of Directors of Oncopeptides AB, Oxthera AB, Oxthera IP AB and Avidicare AB (deputy). He holds a PhD in organic chemistry from the Royal Institute of Technology in Stockholm.

Alain Munoz

Alain Munoz has an MD in Cardiology and Anesthesiology and was the head of the Cardiology department at the University Hospital of Montpellier-Nimes. Alain has numerous publications and has been a member of the scientific committee of the French Drug Agency. Alain has over 25 years’ experience in the pharmaceutical industry as a senior executive within the Sanofi Group and with Fournier Laboratories. He has an in-depth knowledge of the EU, US and Japanese regulatory process and markets. Under his leadership numerous NDA’s were obtained world-wide (Adenocard®, Plavix®, Lipanthyl®/Tricor™, Esclim®, Ikervis®) Alain is Chairman of the Strategic Board of Hybrigenics (ALHYG.PA), a board member of Valneva SE (VLA), a board member of Zealand Pharma (ZEAL), and adviser to KURMA Biofund.

Anders Fink Vadsholt

Anders serves as the CFO of Orphazyme A/S listed at the Copenhagen exchange. He has extensive experience from biotech as well as the financial industry. Before joining Orphazyme, Anders has served in different roles at among others Topotarget, Bankinvest Biomedical Venture, 7TM Pharma and Carnegie Bank.

Anders holds a Master of Science in Commercial Law and Economics from Copenhagen Business School and an MBA in Finance from the Melbourne University.